Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

R&D Systems | Catalog # 11141-SE

R&D Systems
100% Guarantee

Key Product Details

  • R&D Systems HEK293-derived Recombinant Human DPPIV/CD26 Fc Chimera Protein (11141-SE)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

HEK293

Applications

Enzyme Activity
View all DPPIV/CD26 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human DPPIV/CD26 protein
Human CD26
(Asn29-Pro766)
Accession # CAA43118.1		 DIEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Asn29

Predicted Molecular Mass

112 kDa

SDS-PAGE

116-131 kDa, under reducing conditions

Activity

Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC).
The specific activity is >3000 pmol/min/μg, as measured under the described conditions.

Scientific Data Images for Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

Recombinant Human DPPIV/CD26 Fc Chimera Protein Enzyme Activity.

Recombinant Human DPPIV/CD26 Fc Chimera (Catalog # 11141-SE) is measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC).

Recombinant Human DPPIV/CD26 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Human DPPIV/CD26 Fc Chimera Protein (Catalog # 11141-SE) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 116-131 kDa and 230-260 kDa, respectively.

Formulation, Preparation, and Storage

11141-SE
Formulation Supplied as a 0.2 μm filtered solution in Tris and NaCl.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: DPPIV/CD26

Dipeptidyl peptidase 4 (DPPIV, also known as CD26) is an approximately 110 kDa serine exopeptidase that releases Xaa-Pro or Xaa-Ala dipeptides from the N-terminus of oligo- and polypeptides. Mature human DPPIV consists of a 6 amino acid (aa) cytoplasmic tail, a 22 aa transmembrane segment, and a 738 aa extracellular domain (ECD) that contains the catalytic active site (1). DPPIV is expressed as a noncovalent homodimer on the surface of epithelial cells, endothelial cells, and activated lymphocytes, and it can be released by MMP mediated shedding (2). It regulates immune and endocrine function through the cleavage of multiple chemokines, growth factors, and peptide hormones (3,4). It cleaves a range of peptide hormones including Glucagon, Glucagon-like Peptides 1 and 2, GIP, GHRH, Procalcitonin, Neuropeptide Y, and Substance P (5). It is released from adipocytes and induces insulin resistance in adipocytes and skeletal muscle (6). DPPIV also cleaves many chemokines, resulting in altered chemotactic activity (7-10) or impacting chemokine blockade of HIV-1 cellular infectivity depending on the chemokine target (7,9,11). It cleaves human GM-CSF and IL-3 and reduces their ability to promote myeloid cell development (12). In addition to enzymatic cleavage functions, DPPIV interacts with adenosine deaminase on T cells and with caveolin-1 on antigen presenting cells (13), provides costimulatory proliferation and activation signals to both CD4+ and CD8+ T cells (13,14), and serves as a cell entry coreceptor for HIV and coronavirus MERS-CoV-2 (15,16). DPPIV inhibitors are approved for therapeutic treatment in type 2 diabetes (17) and are being explored for treatment of several additional conditions including autoimmune diseases (18).

References

  1. Tanaka, T. et al. (1992) J. Immunol. 149:481.
  2. Rohrborn, D. et al. (2014) FEBS Lett. 588:3870.
  3. Klemann, C. et al. (2016) Clin. Exp. Immunol. 185:1.
  4. Mortier, A. et al. (2016) J. Leukoc. Biol. 99:955.
  5. Waumans, Y. et al. (2015) Front. Immunol. 6:387.
  6. Lamers, D. et al. (2011) Diabetes 60:1917.
  7. Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
  8. Proost, P. et al. (2001) Blood 98:3554.
  9. Ohtsuki, T. et al. (1998) FEBS Lett. 431:236.
  10. Barreira da Silva, R. et al. (2015) Nat. Immunol. 16:850.
  11. Guan, E. et al. (2002) J. Biol. Chem. 277:32348.
  12. Broxmeyer, H.E. et al. (2012) Nat. Med. 18:1786.
  13. Ohnuma, K. et al. (2007) J. Biol. Chem. 282:10117.
  14. Hatano, R. et al. (2013) Immunology 138:165.
  15. Callebaut, C. et al. (1993) Science 262:2045.
  16. Raj, V.S. et al. (2013) Nature 495:251.
  17. Makrilakis, K. (2019) Int. J. Environ. Res. Public Health 16:2720.
  18. Huang, J. et al. (2022) Front. Immunol. 13:830863.

Long Name

Dipeptidyl-peptidase IV

Alternate Names

CD26, DPP4

Entrez Gene IDs

1803 (Human); 13482 (Mouse); 397492 (Porcine); 102133935 (Cynomolgus Monkey)

Gene Symbol

DPP4

Additional DPPIV/CD26 Products

Product Documents for Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

For research use only

Citations for Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

Customer Reviews for Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF and earn rewards!

Have you used Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

View specific protocols for Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF (11141-SE):

Materials
  • Assay Buffer:  25 mM Tris, pH 8.0
  • Recombinant Human DPPIV/CD26 Fc Chimera (rhCD26/Fc) (Catalog # 11141-SE)
  • Substrate: H-Gly-Pro-AMC (Bachem, Catalog # I-1225), 10 mM stock in DMSO
  • F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
  • Fluorescent Plate Reader (Model: SpectraMax M5 by Molecular Devices) or equivalent
  1. Dilute rhCD26/Fc to 0.2 ng/μL in Assay Buffer.
  2. Dilute Substrate to 200 μM in Assay Buffer.
  3. Load into a black plate 50 μL of 0.2 ng/μL rhCD26/Fc, and start the reaction by adding 50 μL of 200 μM Substrate. For Substrate Blank combine 50 μL of Assay Buffer and 50 μL of 200 μM Substrate.
  4. Read at excitation and emission wavelengths of 380 nm and 460 nm, respectively, in kinetic mode for 5 minutes.
  5. Calculate specific activity:

     Specific Activity (pmol/min/µg) =

Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU)
amount of enzyme (µg)

   

*Adjusted for Substrate Blank
**Derived using calibration standard 7-amino, 4-Methyl Coumarin (Sigma, Catalog # A9891)
Per Well:
  • rhCD26/Fc: 0.010 μg
  • Substrate: 100 μM























FAQs

No product specific FAQs exist for this product.

View all FAQs for Proteins and Enzymes